Nucleic Acid-Based Antidiabetic Drug Development Services
Nucleic acid drugs have remarkable efficacy and unique potential in the treatment of diabetes and its complications. Ace Therapeutics is committed to applying our expertise in diabetes R&D to help our customers develop nucleic acid- based antidiabetic drugs. Our one-stop preclinical development services are designed to efficiently and cost-effectively support the development of innovative functional nucleic acids for novel diabetes therapies.
Introduction of Nucleic Acid-Based Antidiabetic Drugs
Research on nucleic acids in diabetes and its complications focuses primarily on tFNAs, miRNAs, and siRNAs. Other functional nucleic acids, such as LNA, ASOs, and DNA origami, have shown significant efficacy in limiting ROS overproduction and attenuating hyperglycemia-induced tissue damage. Nucleic acid drugs are unique molecules for the treatment of diabetes mellitus and its complications due to their high biocompatibility, biodegradability and low toxicity.
Fig. 1 Promoting effects of various functional nucleic acids in diabetic nephropathy. (Wen, W. et al.,2023)
Our Nucleic Acid-Based Antidiabetic Drug Development Services
Ace Therapeutics has an interdisciplinary team specializing in nucleic acid drug discovery, delivery system and preclinical evaluation. Our comprehensive preclinical solutions help clients accelerate nucleic acid-based antidiabetic drug development and provide more effective therapeutic options for diabetes.
We established comprehensive platforms for biological screening, efficacy evaluation, and safety analysis, which are essential for a range of processes, from target discovery to preclinical candidate molecule identification. We are dedicated to supporting your nucleic acid-based antidiabetic drug development program by providing efficient services.
Nucleic Acid-Based Antidiabetic Drug Discovery Services
- Target identification and validation
Our robust capabilities in diabetes target development have enabled us to establish a comprehensive platform for target validation and methodology construction, facilitating new target-based research and nucleic acid drug screening.
Our methodology incorporates bioinformatics analysis to identify potential targets. Subsequently, we assess the impact of target gene silencing or overexpression on glucose homeostasis, insulin secretion, and sensitivity through gene editing techniques and cell models.
- Nucleic acid drug design and optimization
We provide precise nucleic acid molecular design and modification services to optimize efficacy and biological activity for subsequent drug screening.
- High-throughput screening and activity validation
We have established target libraries based on different types of diabetes in order to achieve comprehensive target coverage, including diabetes-related enzymes, receptors, and signaling pathways. We employ high-throughput screening technology to rapidly identify nucleic acid candidates with high efficacy and low toxicity, followed by preliminary efficacy evaluations.
Preclinical Development Services for Nucleic Acid-Based Antidiabetic Drugs
- Preclinical efficacy assessment
We select appropriate cell and animal models to assist our clients in evaluating the antidiabetic activity of potential nucleic acid drug candidates. Our services include assessments of hypoglycemic activity, insulin modulation, and anti-inflammatory or antioxidant activity.
- Pharmacokinetic and pharmacodynamic analysis
Our pharmacokinetic analysis platform provides in vivo analysis of the absorption, distribution, metabolism and excretion of nucleic acid drug candidates.
- Preclinical safety assessment
Our in vivo monitoring of acute toxicity, long-term toxicity, genotoxic toxicity, and reproductive toxicity of nucleic acid-based antidiabetic drugs allows us to provide our clients with comprehensive drug safety data.
Our Capabilities and Technology Platforms
- Advanced bioinformatics tools for diabetes drug target discovery.
- A variety of in vitro models such as pancreatic β-cells, islet cell progenitors, and islet-like organs are used to assess the pharmacodynamic profile and cytotoxicity of nucleic acid drugs.
- Animal models of diabetes constructed by different methods allow comprehensive in vivo pharmacodynamic and safety studies.
- Highly sensitive detection techniques such as LC-MS/MS are used to accurately obtain pharmacokinetic parameters.
Ace Therapeutics provides comprehensive services and support to help clients accelerate their nucleic acid-based antidiabetic drug development programs. We are committed to providing our clients with efficient, customized solutions to help them address challenges encountered during the preclinical development phase. Please contact us for more details and our experts will work with you to develop and deliver more effective drug options for diabetes.
References
- Wen, W.; et al. Functional nucleic acids for the treatment of diabetic complications. Nanoscale Advances. 5.20 (2023): 5426-5434.
- Dwan, B. F.; et al. Nucleic acid-based theranostics in type 1 diabetes. Translational Research. 214 (2019): 50-61.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
Related Services
Related Products
